Search - tctmd.com

Displaying 101 - 120 of 223

Sort: Relevancy | Date

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Caitlin E. Cox

February 23, 2018

News Daily News

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

Yael L. Maxwell

January 31, 2018

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

Presentation AHA 2017

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Presenter: Zuzana Motovska

November 11, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

Advertisement

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Multivessel PCI Improves Outcomes in STEMI Patients With Cardiogenic Shock: Korean Registry

Multivessel Disease Patients See Benefits of Long-term Ticagrelor: PEGASUS-TIMI 54 Analysis

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

RE-DUAL PCI Findings Consistent Across Key Subgroups

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

One-Year Outcomes: Prasugrel vs Ticagrelor in AMI Treated With PPCI PRAGUE-18 Study

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

TCTMD’s Top 10 Most Popular Stories for September 2017

New Performance and Quality Metrics for STEMI and NSTEMI Care

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content